Rare diseases
Investigational molecules
Locations
Study on Capecitabine and Durvalumab for Patients with Removed Biliary Tract Cancer
FranceStudy of Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer
FranceStudy on the Safety of LSTA1 with Standard Care for Patients with Advanced Head and Neck Cancer or Cholangiocarcinoma
SpainStudy of Olaparib and Durvalumab for Patients with Metastatic Pancreatic Cancer and DNA Repair Gene Alterations
SpainStudy of Durvalumab and Tremelimumab for Patients with Colorectal and Endometrial Cancer
SpainStudy on the Safety and Effects of Durvalumab, Tremelimumab, and Bevacizumab in Patients with Advanced Liver Cancer
ItalyStudy on the Effects of Durvalumab, Oleclumab, and Chemotherapy in Patients with Luminal B Breast Cancer
BelgiumStudy of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations
BelgiumStudy on Preoperative Treatment with Gemcitabine, Cisplatin, Durvalumab, and Tremelimumab for Patients with Intrahepatic Cholangiocarcinoma
GermanyStudy of durvalumab, carboplatin and etoposide combination therapy for patients with metastatic large-cell neuroendocrine lung cancer who have not received previous treatment
ItalyStudy of Durvalumab and Regorafenib for Patients with Stage IV Colorectal Cancer with No Evidence of Disease
ItalyStudy of Metronomic Oral Vinorelbine with Durvalumab and Tremelimumab for Patients with Advanced Solid Tumors
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
